Cornerstone Investment Partners LLC Acquires New Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Cornerstone Investment Partners LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, HoldingsChannel reports. The fund acquired 1,372 shares of the medical research company’s stock, valued at approximately $324,000.

A number of other institutional investors have also modified their holdings of CRL. Private Advisor Group LLC grew its position in Charles River Laboratories International by 15.4% in the 1st quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after purchasing an additional 178 shares during the last quarter. Panagora Asset Management Inc. grew its position in Charles River Laboratories International by 236.5% in the 1st quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock worth $773,000 after purchasing an additional 1,913 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Charles River Laboratories International by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock worth $1,917,000 after purchasing an additional 418 shares during the last quarter. Great West Life Assurance Co. Can grew its position in Charles River Laboratories International by 0.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock worth $7,465,000 after purchasing an additional 107 shares during the last quarter. Finally, Raymond James Trust N.A. grew its position in Charles River Laboratories International by 33.7% in the 1st quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after purchasing an additional 384 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CRL has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. UBS Group increased their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Citigroup increased their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Finally, Robert W. Baird increased their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Trading Down 0.7 %

Shares of NYSE:CRL traded down $1.49 during mid-day trading on Friday, hitting $226.06. The stock had a trading volume of 102,101 shares, compared to its average volume of 544,551. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The company has a market cap of $11.64 billion, a PE ratio of 24.71, a P/E/G ratio of 1.80 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company’s 50 day moving average is $253.64 and its 200-day moving average is $220.96.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm’s quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.98 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).